Trials / Conditions / Contiguous Stage II Marginal Zone Lymphoma

Contiguous Stage II Marginal Zone Lymphoma

18 registered clinical trials studyying Contiguous Stage II Marginal Zone Lymphoma.

Status	Trial	Sponsor	Phase
Completed	Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphom NCT02213913	University of Chicago	Phase 1 / Phase 2
Completed	Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Ce NCT01959477	Case Comprehensive Cancer Center	EARLY_Phase 1
Completed	Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hemato NCT01789255	National Cancer Institute (NCI)	Phase 2
Terminated	Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas NCT01805037	Northwestern University	Phase 1 / Phase 2
Completed	Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple NCT02037256	Barbara Ann Karmanos Cancer Institute	N/A
Completed	Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies NCT01273766	Wake Forest University Health Sciences	Phase 2
Active Not Recruiting	Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic NCT01199562	City of Hope Medical Center	—
Terminated	Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma NCT01045928	Case Comprehensive Cancer Center	Phase 1
Terminated	Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer NCT01044745	University of Nebraska	Phase 2
Completed	Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be NCT00891072	National Cancer Institute (NCI)	Phase 1
Completed	Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, NCT01682044	Roswell Park Cancer Institute	Phase 2
Completed	Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem NCT00489203	Fred Hutchinson Cancer Center	Phase 2
Completed	Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma NCT00244855	Fred Hutchinson Cancer Center	Phase 2
Completed	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone To NCT00089011	Fred Hutchinson Cancer Center	Phase 2
Completed	Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Man NCT00058227	National Cancer Institute (NCI)	Phase 1
Completed	Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation NCT00040846	Fred Hutchinson Cancer Center	Phase 2
Completed	Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lympho NCT00017381	National Cancer Institute (NCI)	EARLY_Phase 1
Completed	Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenola NCT00112593	Fred Hutchinson Cancer Center	N/A